1. Home
  2. BTTC vs SNGX Comparison

BTTC vs SNGX Comparison

Compare BTTC & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTTC

Black Titan Corporation Ordinary Shares

N/A

Current Price

$1.37

Market Cap

13.4M

Sector

Health Care

ML Signal

N/A

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.29

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTTC
SNGX
Founded
1990
1987
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.2M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
BTTC
SNGX
Price
$1.37
$0.29
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
22.3K
1.3M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.21
$0.29
52 Week High
$11.22
$6.23

Technical Indicators

Market Signals
Indicator
BTTC
SNGX
Relative Strength Index (RSI) 46.31 19.04
Support Level $1.22 N/A
Resistance Level $1.57 $1.48
Average True Range (ATR) 0.06 0.06
MACD 0.01 -0.06
Stochastic Oscillator 50.00 0.24

Price Performance

Historical Comparison
BTTC
SNGX

About BTTC Black Titan Corporation Ordinary Shares

Black Titan Corp provides human resource and payroll consulting, software implementation, and training solutions using PeopleSoft platforms. The company's revenue is mainly derived from the provision of HCM solutions, followed by the provision of IT staff augmentation, outsourcing and consulting services.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: